Charles River Laboratories International, Inc. (CRL) Financials
CRL Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 7.5 billion | 4.7 billion |
| March 31, 2026 | 7.7 billion | 4.7 billion |
| Dec. 31, 2025 | 7.1 billion | 3.9 billion |
| Sept. 30, 2025 | 7.5 billion | 4.1 billion |
CRL Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | 148.6 million | 19.8 million |
| March 31, 2026 | -14.8 million | 22.4 million |
| Dec. 31, 2025 | 58.6 million | 17.6 million |
| Sept. 30, 2025 | 178.2 million | 23.3 million |
CRL Net Income
Graph available only for paid members. Upgrade to see it.
| Date | Net Income |
|---|---|
| June 30, 2026 | -760000 |
| March 31, 2026 | -14.8 million |
| Dec. 31, 2025 | -276.6 million |
| Sept. 30, 2025 | 55.6 million |
CRL Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 192.0 million | 2.6 billion | 407.7 million |
| March 31, 2026 | 191.8 million | 2.7 billion | 393.1 million |
| Dec. 31, 2025 | 213.8 million | 2.5 billion | 458.7 million |
| Sept. 30, 2025 | 207.7 million | 2.2 billion | 468.7 million |
CRL Shares Outstanding
CRL Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 31.1 million | - | 228.9 million | - |
| March 31, 2026 | 55.9 million | - | 159.4 million | - |
| Dec. 31, 2025 | 89.0 million | - | 187.6 million | - |
| Sept. 30, 2025 | 35.6 million | - | 177.6 million | - |
CRL Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | 1.0 billion | 640.7 million |
| March 31, 2026 | 995.8 million | 716.5 million |
| Dec. 31, 2025 | 994.2 million | 686.4 million |
| Sept. 30, 2025 | 1.0 billion | 666.1 million |
CRL Revenue by Segment
Graph available only for paid members. Upgrade to see it.
CRL
Price: $283.66
52 week price:
Payout Ratio Range:
Earnings Per Share: -4.82 USD
Exchange: NYQ
Sector: Healthcare
Industry: Diagnostics & Research
Country: United States
Volume: 411300
Ebitda: 110.3 millionMarket Capitalization: 13.9 billion